Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway

被引:54
|
作者
Lu, Li [1 ,2 ]
Chen, Guohu [3 ]
Yang, Jingjing [4 ]
Ma, Zhanjun [4 ]
Yang, Yang [4 ]
Hu, Yan [5 ]
Lu, Yubao [4 ]
Cao, Zhangqi [5 ]
Wang, Yan [5 ]
Wang, Xuexi [2 ,5 ]
机构
[1] Lanzhou Univ, Sch Basic Med Sci, Inst Pharmacol, Lanzhou 730000, Gansu, Peoples R China
[2] Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou 730000, Gansu, Peoples R China
[3] Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
[4] Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Gansu, Peoples R China
[5] Lanzhou Univ, Sch Basic Med Sci, Lanzhou 730000, Gansu, Peoples R China
基金
中国国家自然科学基金;
关键词
Mesenchymal stem cells; Glioma cells; Proliferation; Invasion; Epithelial- mesenchymal transition; PI3K/AKT signaling pathway; CANCER-CELLS; CYCLE ARREST; METASTASIS; MECHANISM; THERAPY; EMT; DIFFERENTIATION; TRANSITION; AUTOPHAGY; INVASION;
D O I
10.1016/j.biopha.2019.108625
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Mesenchymal stem cells (MSCs), with the capacity for self-renewal and differentiation into multiple cell types, exhibit the property of homing towards tumor sites and immunosuppression and have been used as tumor-tropic vectors for tumor therapy. However, few studies have investigated the underlying molecular mechanisms that link MSCs to targeted tumor cells. In this study, we elucidated the inhibitory effects and mechanisms of human bone marrow mesenchymal stem cells (hBMSCs) on human glioma U251 cells using a co-culture system in vitro. The anti-tumor activity of co-cultured hBMSCs was assessed by morphological changes, the MTT assay, and Hoechst 33258 staining. Cell apoptosis and cell cycle distribution were evaluated by flow cytometry. Cell migration and invasion were evaluated using a 24-well Transwell chamber. A proteomics approach was used to identify differentially expressed proteins after hBMSCs treatment in U251 cells, and quantitative polymerase chain reaction was used to validate the results. Bioinformatics analyses were also implemented to better understand the identified proteins, and Western blotting analyses were used to analyze the associated proteins. The results showed that hBMSCs could inhibit cell proliferation and induce cell cycle arrest in the G1 phase, resulting in apoptosis of U251 cells. Transwell and Matrigel invasion assays showed that hBMSCs reduced the migration and invasion of U251 cells. Using proteomics, 11 differentially expressed proteins were identified and observed. Bioinformatics analyses indicated that the identified proteins participated in several biological processes and exhibited various molecular functions, mainly related to the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway. Moreover, hBMSCs regulated changes in proteins linked to cell apoptosis and cell cycle progression and inhibited the epithelial-mesenchymal transition (EMT)-like and PI3K/AKT pathway. Taken together, the findings in our study suggest that hBMSCs inhibit U251 cells proliferation and the EMT-like by downregulating the PI3K/AKT signaling pathway, which indicates that hBMSCs have a potential antitumor characteristics and should be further explored in future glioma therapy.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Effects of Platycodin D on Proliferation, Apoptosis and PI3K/Akt Signal Pathway of Human Glioma U251 Cells
    Xu, Chong
    Sun, Guibo
    Yuan, Guangxin
    Wang, Rui
    Sun, Xiaobo
    MOLECULES, 2014, 19 (12) : 21411 - 21423
  • [2] MT1-MMP downregulation via the PI3K/Akt signaling pathway is required for the mechanical stretching-inhibited invasion of bone-marrow-derived mesenchymal stem cells
    Fu, Xiaorong
    Halim, Alexander
    Tian, Boren
    Luo, Qing
    Song, Guanbin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) : 14133 - 14144
  • [3] Prazosin inhibits the proliferation, migration and invasion, but promotes the apoptosis of U251 and U87 cells via the PI3K/AKT/mTOR signaling pathway
    Zhang, Jing
    Fan, Jiye
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 1145 - 1152
  • [4] Tubeimoside-1 induces apoptosis in human glioma U251 cells by suppressing PI3K/Akt-mediated signaling pathways
    Cao, Li-Juan
    Xie, Hai-Tang
    Chu, Zhong-Xia
    Ma, Yue
    Wang, Ming-Ming
    Shi, Zhuang
    MOLECULAR MEDICINE REPORTS, 2020, 22 (02) : 1527 - 1535
  • [5] Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway
    Mao, Junjun
    Wang, Xinping
    Yu, Minghui
    Sun, Chenkun
    CELLULAR AND MOLECULAR BIOLOGY, 2022, 68 (05) : 153 - 160
  • [6] CEP55 promotes cell proliferation and inhibits apoptosis via the PI3K/Akt/p21 signaling pathway in human glioma U251 cells
    Li, Feng
    Jin, Dan
    Tang, Chuanxi
    Gao, Dianshuai
    ONCOLOGY LETTERS, 2018, 15 (04) : 4789 - 4796
  • [7] Knockdown of TRIM37 suppresses the proliferation, migration and invasion of glioma cells through the inactivation of PI3K/Akt signaling pathway
    Tang, Shi-lei
    Gao, Yuan-lin
    Hu, Wen-zhong
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 99 : 59 - 64
  • [8] Mesenchymal stem cells suppress lung inflammation and airway remodeling in chronic asthma rat model via PI3K/Akt signaling pathway
    Lin, Hai-Yan
    Xu, Lei
    Xie, Shuan-Shuan
    Yu, Fei
    Hu, Hai-Yang
    Song, Xiao-Lian
    Wang, Chang-Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (08): : 8958 - 8967
  • [9] Influences of LncRNA SNHG20 on proliferation and apoptosis of glioma cells through regulating the PTEN/PI3K/AKT signaling pathway
    Guo, L-P
    Zhang, Z-J
    Li, R-T
    Li, H-Y
    Cui, Y-Q
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (01) : 253 - 261
  • [10] Downregulation of Pygopus 2 inhibits vascular mimicry in glioma U251 cells by suppressing the canonical Wnt signaling pathway
    Wang, Haidong
    Fu, Jianhua
    Xu, Dianshuang
    Xu, Weiwei
    Wang, Shiyong
    Zhang, Liu
    Xiang, Yongsheng
    ONCOLOGY LETTERS, 2016, 11 (01) : 678 - 684